Foralumab is classified as a fully human anti-CD3 monoclonal antibody. As a specialized biologic therapeutic agent, it is engineered to bind specifically to the CD3 receptor complex located on the surface of T cells. Unlike older murine or chimeric antibodies that often trigger adverse immune reactions, foralumab's fully human structure minimizes immunogenicity. When administered via an innovative intranasal route, it stimulates regulatory T cells (Tregs) locally to suppress harmful inflammatory cascades while avoiding the severe systemic side effects typically linked to intravenous antibody infusions.